Cairo, Egypt, November 2025 – A comprehensive new framework, “The Egyptian Guideline for Medical Device Vigilance System,” is set to dramatically reshape how medical device manufacturers operate in the country, placing rigorous new obligations on companies from pre-market approval to post-market monitoring. The goal of this guidance, issued by the Egyptian Drug Authority (EDA), is simple but powerful: to improve patient safety by quickly identifying, reporting, and fixing issues with devices once they are in use, ultimately “reducing the repetition of the same type of adverse events”. Here’s a breakdown of the critical new mandates and how they impact device manufacturers.
THE CORE IMPACT: A MANDATORY VIGILANCE SYSTEM
The new guideline makes a manufacturer-led vigilance system mandatory. This system requires you to systematically collect and evaluate all experience gained from your devices on the market to ensure they remain safe and perform as intended.
The Medical Device Safety Unit (MDSU) is now the central regulatory body, and manufacturers are obligated to collect information on product risks and transmit it directly to the MDSU.
NEW "BEFORE-YOU-SELL" REQUIREMENTS
The new rules start even before a device hits the shelves:
- Pre-Market Safety Assurance: For initial registration or re-registration, manufacturers of certain low-to-medium-risk devices must submit a formal Declaration confirming that they have had no recalls, Field Safety Notices (FSNs), or other regulatory actions in the prior three years.
- High-Risk Scrutiny: For higher-risk devices, manufacturers must submit a detailed Pre-market safety report and a National Appendix summarizing the device’s safety and performance data in a format compliant with local regulations.
CRITICAL POST-MARKET RESPONSIBILITIES
Once a device is marketed, manufacturers face an extensive set of ongoing obligations focused on continuous monitoring and rapid response.
1. Mandatory Surveillance Systems
You must now plan, document, implement, and maintain a Post-Market Surveillance (PMS) system that is proportionate to your device’s risk class. This plan must include clear objectives, such as:
- Identifying any new hazards or situations that change the device’s risk profile.
- Tracking instances of misuse or unforeseen side-effects.
- Documenting any malfunction that impacts the fundamental benefit-risk analysis.
This continuous monitoring requires you to regularly submit a Post-Market Surveillance Report (PMSR) and a comprehensive Periodic Safety Update Report (PSUR) summarizing the worldwide safety data for your device.
2. Incidents and Complaints
Manufacturers must now have robust systems for reporting and investigation:
- Safety Officer: You must appoint a dedicated Safety Officer who acts as the authorized person for communication with the MDSU.
- Tracking System: A comprehensive tracking system is required to record all supply and distribution information, which is essential for complaint handling.
- Immediate Reporting: When a serious incident occurs, you must investigate, and if confirmed, provide an initial report to the MDSU without delay, followed by follow-up and final reports.
- Trend Reporting: Manufacturers must now submit a Trend Report (TR) if there is a statistically significant increase in the frequency or severity of non-serious incidents that could impact the benefit-risk analysis.
3. Field Safety Corrective Action (FSCA) and Safety Notices
Field Safety Corrective Action (FSCA) refers to any action taken by a manufacturer to reduce the risk of serious harm associated with a device already on the market. This is where compliance becomes critical:
Requirement | Details for Manufacturers |
Field Safety Notice (FSN) | An FSCA must be communicated to customers/users via an FSN. |
MDSU Approval | You must issue the FSN and get MDSU approval for its content and the implementation plan before distribution. (Note: In urgent recall cases, you can start immediate distribution without waiting for the approval letter). |
Documented Proof | You must maintain documented proof that you notified all affected importers, distributors, healthcare providers, and users about the FSN. |
Action Completion | After the corrective actions are complete, you must submit a “Confirmation Statement for Completing the Corrective Action” to the MDSU. |
This new guideline signals a clear shift toward proactive, verifiable accountability, ensuring that medical devices maintain the highest standards of safety and performance throughout their entire lifecycle in the Egyptian market.